Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2023-10-10 00:00:00 ET · period of report 2023-10-10 · accession 0000897069-23-001444 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-10 | 2023-10-10 | PCSA | Young David | Pres. Research, Development, Dir, 10% | A - Grant | $0.24 | +142.0K | 612.4K | +30% | +$34.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-10 | A | A | 142,000 | $0.24 | 612,424 | D | — | — |